Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Ming, Ming ^a   Sinnett Smith, James ^a,b   Wang, Jia ^a   Soares, Heloisa P ^a   Young, Steven H ^a,b   Eibl, Guido ^a,b   Rozengurt, Enrique ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; BERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ANTIDIABETIC AGENT; INSULIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NEUROTENSIN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOGENESIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CARCINOMA, PANCREATIC DUCTAL; DNA REPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

BOVINAE; MUS;

ACETYL-COA CARBOXYLASE; ADENOCARCINOMA; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA REPLICATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; NEUROTENSIN; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84916894620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114573     Document Type: Article

References (92)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, et al. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res 74: 2913-2921.
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64: 9-29.
3. Brand RE, Tempero MA (1998) Pancreatic cancer. Curr Opin Oncol 10: 362-366.
4. Rozengurt E, Walsh JH (2001) Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 63: 49-76.
5. Rozengurt E (2002) Neuropeptides as growth factors for normal and cancer cells. Trends Endocrinol Metabol 13: 128-134.
6. Rozengurt E (2007) Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213: 589-602.
7. Heasley LE (2001) Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20: 1563-1569.
8. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94.
9. Ryder NM, Guha S, Hines OJ, Reber HA, Rozengurt E (2001) G protein-coupled receptor signaling in human ductal pancreatic cancer cells: Neurotensin responsiveness and mitogenic stimulation. J Cell Physiol 186: 53-64.
10. Guha S, Rey O, Rozengurt E (2002) Neurotensin Induces Protein Kinase C-dependent Protein Kinase D Activation and DNA Synthesis in Human Pancreatic Carcinoma Cell Line PANC-1. Cancer Res 62: 1632-1640.
11. Guha S, Lunn JA, Santiskulvong C, Rozengurt E (2003) Neurotensin Stimulates Protein Kinase Cdependent Mitogenic Signaling in Human Pancreatic Carcinoma Cell Line PANC-1. Cancer Res 63: 2379-2387.
12. Kisfalvi K, Guha S, Rozengurt E (2005) Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J Cell Physiol 202: 880-890.
13. Seckl MJ, Higgins T, Widmer F, Rozengurt E (1997) [D-Arg1, D-Trp5,7,9, Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 57: 51-54.
14. Sinnett-Smith J, Santiskulvong C, Duque J, Rozengurt E (2000) [D-Arg(1), D-Trp(5,7,9), Leu(11)]substance P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3 cells]. J Biol Chem 275: 30644-30652.
15. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, et al. (2005) Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, D-Trp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65: 2738-2745.
16. Elek J, Pinzon W, Park KH, Narayanan R (2000) Relevant genomics of neurotensin receptor in cancer. Anticancer Research 20: 53-58.
17. Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, et al. (2000) Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 6: 566-571.
18. Reubi JC, Waser B, Friess H, Bèuchler M, Laissue J (1998) Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42: 546-550.
19. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, et al. (2007) Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996-1005.
20. Kisfalvi K, Rey O, Young SH, Sinnett-Smith J, Rozengurt E (2007) Insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR-Dependent Pathway. Endocrinology 148: 3246-3257.
21. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer. Clin Cancer Res 16: 2505-2511.
22. Young SH, Rozengurt E (2010) Crosstalk between insulin receptor and G protein-coupled receptor signaling systems leads to Ca(2+) oscillations in pancreatic cancer PANC-1 cells. Biochem Biophys Res Commun 401: 154-158.
23. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, et al. (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129: 504-511.
24. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92: 2076-2083.
25. Larsson SC, Bergkvist L, Wolk A (2006) Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am J Clin Nutr 84: 1171-1176.
26. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, et al. (2007) Prediagnostic plasma Cpeptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-2109.
27. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, et al. (2007) Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med 5: 21.
28. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, et al. (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Jama 294: 2872-2878.
29. Reeves GK, Pirie K, Beral V, Green J, Spencer E, et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Bmj 335: 1134.
30. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, et al. (2005) Fasting serum glucose level and cancer risk in Korean men and women. Jama 293: 194-202.
31. Verhage BA, Schouten LJ, Goldbohm RA, van den Brandt PA (2007) Anthropometry and pancreatic cancer risk: an illustration of the importance of microscopic verification. Cancer Epidemiol Biomarkers Prev 16: 1449-1454.
32. Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44: 293-297.
33. Ben Sahra I, Le Marchand-Brustel Y, Tanti J, Bost F (2010) Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? Mol Cancer Ther 9: 1092-1099.
34. Pernicova I, Korbonits M (2014) Metformin[mdash]mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10: 143-156.
35. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646.
36. Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, et al. (2004) Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. Gynecol Endocrinol 19: 125-133.
37. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, et al. (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8: 501-505.
38. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
39. Kalender A, Selvaraj A, Kim SY, Gulati P, Brulé S, et al. (2010) Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner. Cell Metabol 11: 390-401.
40. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
41. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
42. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
43. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
44. Sinnett-Smith J, Kisfalvi K, Kui R, Rozengurt E (2013) Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 430: 352-3527.
45. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013) Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells. PLoS One 8: e57289.
46. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545.
47. Yue W, Yang CS, DiPaola RS, Tan X-L (2014) Repurposing of Metformin and Aspirin by Targeting AMPK-mTOR and Inflammation for Pancreatic Cancer Prevention and Treatment. Cancer Prev Res 7: 388-397.
48. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, et al. (2014) Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. Cancer Prev Res 7: 867-885.
49. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, et al. (2014) Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intentionto-Treat Trial. Diabetes Care 37: 2522-2532.
50. Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL (2009) Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488.
51. Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D (2012) Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clin Cancer Res 18: 2905-2912.
52. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
53. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264.
54. Hwang JT, Kwon DY, Yoon SH (2009) AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol 26: 17-22.
55. Zhao H-L, Sui Y, Qiao C-F, Yip KY, Leung RKK, et al. (2012) Sustained Antidiabetic Effects of a Berberine-Containing Chinese Herbal Medicine Through Regulation of Hepatic Gene Expression. Diabetes 61: 933-943.
56. Mantena SK, Sharma SD, Katiyar SK (2006) Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5: 296-308.
57. Zhang Y, Li X, Zou D, Liu W, Yang J, et al. (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559-2565.
58. Xie W, Gu D, Li J, Cui K, Zhang Y (2011) Effects and Action Mechanisms of Berberine and Rhizoma coptidis on Gut Microbes and Obesity in High-Fat Diet-Fed C57BL/6J Mice. PLoS ONE 6: e24520.
59. Xia X, Yan J, Shen Y, Tang K, Yin J, et al. (2011) Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. PLoS ONE 6: e16556.
60. Lo T-F, Tsai W-C, Chen S-T (2013) MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and Inhibits Hepatoma Cell Growth. PLoS ONE 8: e75628.
61. Wang L, Cao H, Lu N, Liu L, Wang B, et al. (2013) Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells. PLoS ONE 8: e56666.
62. Mantena SK, Sharma SD, Katiyar SK (2006) Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5: 296-308.
63. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, et al. (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11: 554-565.
64. Pinto-Garcia L, Efferth T, Torres A, Hoheisel JD, Youns M (2010) Berberine inhibits cell growth and mediates caspase-independent cell death in human pancreatic cancer cells. Planta Med 76: 1155-1161.
65. Wang Y, Liu Q, Liu Z, Li B, Sun Z, et al. (2012) Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 734: 20-29.
66. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435.
67. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-307.
68. Kheir MM,Wang Y, Hua L, Hu J, Li L, et al. (2010) Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol 48: 1105-1110.
69. Domitrovic R, Jakovac H, Blagojevic G (2011) Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice. Toxicology 280: 33-43.
70. Kisfalvi K, Moro A, Sinnett-Smith J, Eibl G, Rozengurt E (2013) Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts. Pancreas 42: 781-785.
71. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614.
72. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, et al. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228.
73. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
74. Oakhill JS, Steel R, Chen Z-P, Scott JW, Ling N, et al. (2011) AMPK Is a Direct Adenylate Charge-Regulated Protein Kinase. Science 332: 1433-1435.
75. Gowans Graeme J, Hawley Simon A, Ross Fiona A, Hardie DG (2013) AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation. Cell Metabol 18: 556-566.
76. Rizvi F, Heimann T, Herrnreiter A, O'Brien WJ (2011) Mitochondrial Dysfunction Links Ceramide Activated HRK Expression and Cell Death. PLoS ONE 6: e18137.
77. Bandi H, Ferrari S, Krieg J, Meyer H, Thomas G (1993) Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem 268: 4530-4533.
78. Cool B, Zinker B, Chiou W, Kifle L, Cao N, et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabol 3: 403-416.
79. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, et al. (2007) Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family. J Biol Chem 282: 32539-32548.
80. Mahata S, Bharti A, Shukla S, Tyagi A, Husain S, et al. (2011) Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer 10:25.
81. Wang L, Liu L, Shi Y, Cao H, Chaturvedi R, et al. (2012) Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor. PLoS ONE 7: e36418.
82. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint. Mol Cell 30: 214-226.
83. Tzatsos A, Tsichlis PN (2007) Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282: 18069-18082.
84. Ning J, Clemmons DR (2010) AMP-Activated Protein Kinase Inhibits IGF-I Signaling and Protein Synthesis in Vascular Smooth Muscle Cells via Stimulation of Insulin Receptor Substrate 1 S794 and Tuberous Sclerosis 2 S1345 Phosphorylation. Mol Endocrinol 24: 1218-1229.
85. Liang J, Mills GB (2013) AMPK: A Contextual Oncogene or Tumor Suppressor? Cancer Res 73: 2929-2935.
86. Faubert B, Boily G, Izreig S, Griss T, Samborska B, et al. (2013) AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo. Cell Metabol 17: 113-124.
87. Zhou G, Wang J, Zhao M, Xie T-X, Tanaka N, et al. (2014) Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Mol Cell 54: 960-974.
88. Jeon S-M, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-665.
89. Yan M, Gingras M-C, Dunlop EA, Nou xEb, et al. (2014) The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J Clin Invest 124: 2640-2650.
90. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, et al. (2014) Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 111: E435-E444.
91. Ducommun S, Ford RJ, Bultot L, Deak M, Bertrand L, et al. (2014) Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. Am J Physiol-Endocrinol Metab 306: E688-E696.
92. Scott JW, Ling N, Issa SA, Dite TA, O'Brien MT, et al. (2014) Small Molecule Drug A-769662 and AMP Synergistically Activate Naive AMPK Independent of Upstream Kinase Signaling. Chem Biol 21: 619-627.